This document repository is meant to serve as the start of a crowd-sourced collection of information, documentation, protocols and other resources for public health laboratories intending to sequence SARS-CoV-2 coronavirus samples in the coming weeks. This is admittedly a limited first draft, but will continued to collate useful information as additional protocols, tools, and resources are added, and as best practices are identified. While some of the resources here are directed specifically to US state and local public health laboratories in support of diagnostic testing, sequencing and response, we hope that this is a useful resource for the global laboratory community, as we respond to this pandemic threat.
This collection was originally established, maintained and curated by Duncan MacCannell from the Office of Advanced Molecular Detection (AMD) at the Centers for Disease Control and Prevention (CDC). It has incorporated collaborative edits from more than two dozen submitters throughout the world, and is actively maintained by Michael Weigand and the CDC TOAST Team. Please feel free to suggest additions, edits, clarifications and corrections -- either by posting an issue, filing a pull request or by contacting me directly by email or twitter. In the meantime, I'll continue to add and mirror useful resources here as they become available.
- Sequencing Protocols
- Bioinformatic Tools, Scripts and Workflows
- Quality Management
- Submitting to Public Sequence Repositories
- Linking Sequence Accessions
- Other Useful References and Resources
- Notices and Disclaimers
Disclaimer
The findings and conclusions in this document and the attendant repository are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or by the U.S. Department of Health and Human Services.
The following sequencing protocols, checklists and job-aids are primarily designed for the Oxford Nanopore MinION, and have been kindly shared by research groups throughout the world (please see individual protocols for attribution and citing purposes). Even so, most of these protocols should scale to larger ONT instruments without significant modifications.
This protocol was developed and released by the fine folks at ARTIC Network, and was subsequently refined based on comments from Itokawa et al, which identified potential issues and proposed an alternate L18 primer.
-
ARTIC on Illumina - Complete Walk-through - Grubaugh/Andersen/Loman labs
-
Integrated bioinformatics (RAMPART) - documentation below under bioinformatics methods.
UPDATE: Recent preprint by Tyson et al. and the ARTIC Network team describes a greatly streamlined workflow for ARTIC-Nanopore sequencing of SARS-CoV-2, including functional multiplexing library construction up to 96 samples. Protocol and details are here.
The Victorian Infectious Diseases Reference Laboratory (VIDRL) at the Peter Doherty Institute for Infection and Immunity released two protocols for the ONT MinION, which they successfully used to sequence early Australian SARS-CoV-2 samples.
Illumina's Research and Development group has recently developed and validated a custom, research use only (RUO) enrichment sequencing strategy based on their Nextera Flex chemistry.
The NIAID laboratory team in Cambodia, in collaboration with UCSF, CZBioHub and IPC, has released a metagenomic sequencing with spiked primer enrichment (MSSPE) protocol for SARS-CoV-2. The protocol is available on protocols.io.
Illumina's technical note on sequencing coronavirus samples using a comprehensive metagenomic sequencing approach was one of the earlier protocols released for SARS-CoV-2, and remains an effective option for shotgun sequencing.
The Sabeti lab, at the Broad Institute, released a probe set for comprehensive whole-genome capture of SARS-CoV-2 and respiratory-related viruses (human-infecting coronaviruses, HRSV, HMPV, HPIVs, Human mastadenovirus A-G, Enterovirus A-E, Rhinovirus A/B/C, influenza A/B/C). The probe set is available as V-Respiratory on the probe designs page of the CATCH repository. It was initially released in January, 2020 and most recently updated in March, 2020. Probes can be ordered from Twist Bioscience; we have used the protocol for Twist custom panels with slight modifications for low input Nextera XT libraries.
A number of different laboratories have implemented derivatives of the ARTIC amplicon scheme on Illumina.
- Protocol from the Grubaugh lab at Yale (gdoc)
- Virgina DCLS has a detailed ARTIC-on-Illumina protocol, including worksheets, flowcharts and helpful hints.
- Joel Sevinsky and the intrepid team at StaPH-B have adapted ARTICv3 for Illumina for public health laboratories that are already configured for PulseNet sequencing. - SARS-CoV-2 Sequencing on Illumina MiSeq using ARTIC Protocol: Part 1 - Tiling PCR - SARS-CoV-2 Sequencing on Illumina MiSeq using ARTIC Protocol: Part 2 - Illumina DNA Flex
- Freed and Silander developed a modified ARTIC protocol with 1200bp inserts(primers)
- Gohl and collagues at UMN describe an elegant tailed amplicon approach that enables ARTIC without the need for ligation or tagmentation steps (BMC Genomics)(protocols.io)
- Sorensen, Karst and Knutsson from Alborg University have described a tailed long amplicon derivative of ARTIC (protocols.io)
PacBio maintains a COVID-19 landing page with updated resources on existing protocols and SARS-CoV2-2 assay development recommendations.
a) Sinai 1.5kb and 2kb tiled amplicon protocol and PacBio barcoding options b) Eden 2.5kb tiled amplicon protocol and PacBio barcoding options c) CDC 500bp and 900bp tiled amplicon protocol and PacBio barcoding options
Files are mirrored here.
A number of laboratories have reported success with the Ion AmpliSeq SARS-CoV-2 Research panel for the IonTorrent S5 platform. Amplicon strategies, such as ARTIC, should also work for the S5, and we'd welcome the addition of any working protocols and other resources to this section.
- Ion AmpliSeq SARS-CoV-2 Research Panel for GeneStudio S5
- Ion AmpliSeq SARS-CoV-2 Research Panel for the Genexus System
Staff and students from Thomas Friedrich and Dave O'Connor's laboratories at UWMadison have put together a tandem sequencing protocol and bioinformatic workflow that incorporates Illumina and ONT sequence. While this may be overkill for routine or high-throughput public health purposes, the necessary protocols, scripts and documentation are available here.
A few different sites have resources that are foundational to most bioinformatics analysis.
- NCBI and EBI are both INSDC public repositories, and contain all public access sequences, annotation, analysis and derived data. NCBI has added a specific landing page for SARS-CoV-2 research resources, available here.
- GISAID was put into place to provide a framework for open sharing of influenza sequence data, while maintaining strict governance over the use of data and attribution to sequence submitters.
- The original SARS-CoV-2 reference sequence, "Wuhan-Hu-1", submitted by Zhang Yongzhen and colleagues is mirrored from NCBI in the
sequencesfolder here. In that folder, you will also find a dated set of public genomes in that folder, downloaded from NCBI on a semi-regular basis. NB: These are consensus sequences manually pulled from NCBI Genbank. More complete sets of sequences are available at the GISAID public access repository, which requires account registration and adherence to a strict code of conduct. - Genexa has put together a page with precomputed kmer sets, indicies, reference sequences, and a number of other useful resources for bioinformatic analysis of SARS-CoV-2 NGS data.
- Illumina has just released a SARS-CoV-2 Software Toolkit, including premade RT-PCR and sequencing workflows for ClarityLIMS, FPGA (DRAGEN)-powered bioinformatics, and direct submission to GISAID.
This section describes the basic bioinformatic workflow that the Viral Discovery laboratory in NCIRD, and other teams at CDC use for quality assessment, assembly and comparison of coronavirus sequences. IRMA, the Iterative Refinement Meta-Assembler developed by CDC's Influenza Division for routine influenza surveillance, has recently been updated to support both ebolavirus and coronavirus assembly tasks. While IRMA isn't used for all SARS-CoV-2 assemblies at CDC, it is a powerful tool for complex or problematic samples and datasets.
- Emerging Infectious Diseases
- IRMA: Iterative Refinement Meta-Assembler is available here.
- CLCbio (Jonathan Jacobs) has released workflows for the NCIRD/DVD protocols on Illumina and Nanopore. Older versions available here.
QIAGEN has released example workflows and tutorials for analyzing Illumina and Oxford Nanopore SARS-CoV-2 sequence data using CLC Genomics Workbench v20.0.3. Note - these workflows are "Research Use Only" (RUO), and may need to modified to fit upstream protocols. Free temporary licenses for CLC GWB and IPA are available, as well as a series of webinars and tutorials are available to familiarize users with the workflows. Jonathan Jacobs and Leif Schauser are available for user support and specific questions.
- Temporary licenses for CLC Genomics Workbench and Ingenuity Pathway Analysis
- SARS-CoV-2 Analysis Tutorial with Nanopore Data (Figure)
- SARS-CoV-2 Workflow and Tutorial Data for Nanopore Data (Figure)
- CLC Illumina Workflow v1
- Additional CLC Genomics Workbench Workflows developed by Jonathan Jacobs for QIAseq SARS-CoV-2 panel, Ion AmpliSeq SARS-COV-2 panel, and ARTICv3 Nanopore & llumina panels.
The ARTIC Network has released detailed instructions on how to setup and configure the conda environment needed to run their analysis pipelines. These are complete bioinformatic workflows, including runtime visualization, basecalling, mapping/assembly and reporting in a single, portable environment. The artic-nCoV2019 repo includes source code and build instructions for a custom RAMPART configuration. Additional instructions and documentation are available below.
BugSeq has support for automatic SARS-CoV-2 analysis (quality control, consensus sequence generation, variant calling and lineage typing) from nanopore sequencing data. This analysis is triggered by detection of SARS-CoV-2 in data submissions and is automatically tailored for experimental design (metagenomic and all amplicon designs [ARTIC, Midnight, NEB VSS and more] are currently supported). Analysis is as simple as uploading FASTQ files to the BugSeq secure and private platform. Additional information and documentation are available below:
One Codex has added support to its analysis platform for analyzing SARS-CoV-2 samples. This analysis (example) will be automatically run on any samples with SARS-CoV-2 reads. One Codex is making analysis of SARS-CoV-2 samples available free of charge for all users sharing their results and data publicly. Additional information and documentation are available below:
The Broad Institute's viral genomics analysis tools can assist with assembly, metagenomics, QC, and NCBI submission prep, for Illumina-generated data on viral genomes. It is available in the following forms:
- The Terra cloud platform (workspace including example SARS-CoV-2 data from SRA, blog post, getting started)
- The DNAnexus cloud platform (workflows)
- The Dockstore tool repository service - integrates with several cloud platforms, or download to run on-prem (workflows)
- Github (workflows)
The tools include:
- denovo and reference based assembly
- short read alignment and coverage plots
- krakenuniq metagenomic classification
- NCBI: SRA download, Genbank annotation download, Genbank submission prep
- multiple alignment of genomes w/MAFFT
- Illumina basecalling & demux, metrics, fastQC, ERCC spike-in counter
Genome Detective virus tool does QC, assembly and identification of SARS-CoV-2 from a wide range of sequencing protocols (metagenomic or targeted sequencing).
Raw sequence read files (FASTQ) can be uploaded directly in this web-based tool, and consensus sequences can be subsequently analyzed by the the Coronavirus Typing Tool.
Example output:
CosmosID has recently posted a blog entry on their site, describing how to use their web-based analysis platform to analyze SARS-CoV-2 data.
@ErinYoung and Kelly Oakeson at the Utah Department of Health have outlined their bioinformatics approach for SARS-CoV-2 sequences using ARTIC primers, sequenced on Illumina. Now available as the Cecret workflow.
Workflows are available for the Galaxy Platform
- Cheoinformatics: Virtual screening of the SARS-CoV-2 main protease
- Genomics: Analysis of COVID-19 data using Galaxy, BioConda and public research infrastructure
- ARTIC: Amplicon analysis using Artic workflows
These repositories provide best practise workflows for genomic and chemoinformatic analyses for SARS-CoV-2 data. In addition to providing tools and workflows we provide free public computational infrastrcture for immediate use by anyone worldwide using a consortium of Galaxy instances from US, EU, and Australia.
The chemoinformatics workflows can be used to conduct fragment screening using molecular docking. This has already been done for the SARS-COV-2 main protease (MPro) by the Diamond Light Source's XChem team, InformaticsMatters and the European Galaxy Team. The genomics workflows use entirely open source software and open access platforms to perform (1) data pre-processing, (2) genome assembly, (3) estimation of MRCA timing, (4) analysis of intrahost variation, (5) analysis of substitutions within the S gene, and (6) analysis of recombination and selection.
The Epitranscriptomics and RNA Dynamics Lab (Novoa) and the Bioinformatics Core Facility (BioCore at the CRG have released a set of tools and resources to support the analysis of nanopore direct RNA sequencing data.
Applied Maths/bioMerieux have released a plugin for BioNumerics that facilitates the processing and analysis of SARS-CoV-2 genomic sequences, whether downloaded from a public data repository or generated locally. More info on the tool and a tutorial can be found here.
The State Public Health Bioinformatics (StaPH-B) consortium has made their Monroe workflow and Cecret workflow accessible through the StaPH-B ToolKit. Both utilize Nextflow to produce consensus genome assemblies from amplicon libraries (e.g. ARTIC) sequenced on Illumina platforms and Monroe includes added functionality for Oxford Nanopore data as well as basic cluster analysis from assembled SARS-CoV-2 genomes. According to StaPH-B, Cecret is the generally preferred workflow.
Fastv is a little-weight independent tool for ultra-fast identification of SARS-CoV-2 and other microbes from sequencing data. It detects SARS-CoV-2 sequences from FASTQ data, generates JSON reports and visualizes the result in HTML reports. It supports both short reads (Illumina, BGI, etc.) and long reads (ONT, PacBio, etc.). More information can be found here.
EDGE COVID-19 is a standardized web-based workflow for automated reference-based genome assembly of SARS-CoV-2 samples. The workflow accommodates Illumina or Oxford Nanopore Technologies data, performs read mapping and provides static and interactive figures/graphs to explore quality and any discovered SNPs, Variants, Gaps, and indels. Given raw FASTQ file(s) from amplicon-based methods (ARTIC, CDC) or shotgun sequencing (including from enrichment protocols), EDGE COVID-19 automates the production of a SARS-CoV-2 genome that is ready for submission to GISAID or GenBank. We have automated the process to submit high quality genomes to GISAID (with required metadata) and we are working on a similar process for SRA and GenBank.
Here is a link to the arXiv paper describing the workflow.
Our other COVID-19 related efforts can be found here.
16. MiCall: Pipeline for processing NGS data to genotype human RNA viruses like SARS-CoV-2, HIV and hepatitis C
MiCall processes NGS read data from platforms like Illumina by either assembling them or mapping them to a set of reference sequences. Then, it reports consensus sequences, variant mixtures, and quality control reports. For HIV and hepatitis C, it also reports drug resistance interpretations of the variant mixtures.
MiCall is open-source software and comes packaged to be run under Docker or Singularity, to make installation easy. It's also available to run on Illumina's BaseSpace web service, but the SARS-CoV-2 support is not yet available there.
17. EzCOVID19: A bioinformatics platform for rapid detection, identification, and characterization of the SARS-CoV-2 virus
ChunLab/EzBiome has developed a cloud-based bioinformatics platform, EzCOVID19, for rapid detection, identification, and characterization of the SARS-CoV-2 virus from raw metagenomic, metatranscriptomic, RNA-seq, and/or isolate (amplicon or enrichment) NGS data suspected of containing the SARS-CoV-2 virus. EzCOVID19 provides scientists with a consensus genome assembly along with statistics related to genome coverage, depth metrics, and coverage plots relative to the reference SARS-CoV- 2 genome. EzCOVID19 enables characterization and typing of the entire viral genome, when the user obtains adequate coverage of the genome. It provides Single Nucleotide Variant (SNV) information, including a graph and table with detected variants in the SARS-CoV-2 genome, identifies most similar genomes available in the reference databases, based on alignment statistics and SNVs, including a maximum likelihood or parsimony based similarity tree decorated with SNV profiles. It also offers classification or typing of the queried genome using EzBioCloud’s SNP based classification scheme of SARS-CoV-2 variants, including an evolutionary analysis of the detected SARS-CoV-2 type along with other types observed among publicly available SARS-CoV-2 genomes.
Here is an example of EzCOVID19 analysis outputs. Please contact [email protected] for any questions or queries.
The Chan Zuckerberg BioHub and Chan Zuckerberg Initiative have put together updates to the IDSeq platform, enabling users to analyze MSSPE or ARTICv3 amplicon SARS-CoV-2 sequence data, in addition to their existing tools for metagenomic analysis. They have also provided a number of workflows over on their Github site, including an automated pipeline for building SARS-CoV-2 consensus genomes WDL link.
nf-core is a community effort to collect a curated set of analysis pipelines built using Nextflow. nf-core/viralrecon is a bioinformatics analysis pipeline used to perform assembly and intra-host/low-frequency variant calling for viral samples. The pipeline supports both Illumina and Nanopore sequencing data. For Illumina short-reads the pipeline is able to analyse metagenomics data typically obtained from shotgun sequencing (e.g. directly from clinical samples) and enrichment-based library preparation methods (e.g. amplicon-based: ARTIC SARS-CoV-2 enrichment protocol; or probe-capture-based). For Nanopore data the pipeline only supports amplicon-based analysis obtained from primer sets created and maintained by the ARTIC Network.
This section will describe best practices for laboratory and bioinformatic quality assurance, including preflight checks for sequence and metadata submission to public repositories.
CDC's Enterics Disease Laboratory Branch and Respiratory Viruses Branch have developed SC2CLIA Cecret, a CLIA compliance ready SARS-CoV-2 bioinformatics workflow. It adds CDC-specific QA/QC metrics, CLIA-ready reports, database storage stubs, and consensus sequence uploads for NCBI to the Cecret workflow.
The FDA, in collaboration with CDC, BEIR, UMaryland IGS, and others, have recently put together reference sequences, and materials for NGS sequencing and assay development. These resources will be invaluable to many laboratories implementing NGS quality management programs.
-
SanitizeMe - Scripts and an X11 GUI for removing human host sequences from metagenomic data before SRA submission.
-
NCBI human read removal tool - aka the 'sra-human-scrubber' is a CLI script to remove human sequence containing reads from fastq files.
-
to do: I'd love for people to help describe their actual QC processes.
- Metagenomic dataset from Lemieux et al, 2020. Phylogenetic reconstruction should produce a tree resolving three clades, which correspond to three introductions, and an outgroup.
- A collection of datasets organized by CDC's Technical Outreach and Assistance for States Team (TOAST), 🍞. Includes sample replication with different sequencing preparation or instruments, representatives from VOC/VOI and non-VOC/VOI lineages, and failed QC runs.
- A detailed list of mutations observed by public health or academic institutions engaged in sequencing SARS-CoV-2 clinical specimens. Submitters from the community are expected to confirm the validity of mutations by inspecting read mapping results. This resource is maintained by CDC's Technical Outreach and Assistance for States Team (TOAST), 🍞.
The draft WHO code of conduct for open and timely sharing of pathogen genetic sequence data during outbreaks of infectious disease lays out an important and sensible set of principles for sharing pathogen genetic sequence data during outbreaks of international importance. The text is available here.
We are proposing simplified naming conventions for sequences submitted to GISAID and NCBI from US public health and clinical laboratories.
| COUNTRY | / STATE-LAB-SAMPLE / | YEAR |
|---|---|---|
USA |
/ CA-CDPH-S001 / |
2020 |
USA |
/ UT-UPHL-0601 / |
2020 |
USA |
/ AZ-TGEN-N1045 / |
2020 |
USA |
/ ID-UW-0316 / |
2020 |
The proposed convention is as follows: 1) country (USA). 2) The middle sample identification cell should include two-letter state (eg: CA), an abbreviated identifier for the submitting lab (eg: CDPH), as desired, and a unique sequence identifier (eg:01, S01, 454, ...), with all three terms separated by hyphens.
For states with only one submitting laboratory (which should be most), the identifier for the submitting laboratory may be omitted, resulting in a simple, state-level identifier such as USA/UT-573/2020.
These recommendations are roughly compatible with existing submissions to GISAID and NCBI, but are completely open for debate. The current ICTV recommendations are here, with the original biorXiv here.
The National Center for Biotechnology has established a custom landing page for SARS-CoV-2 sequences and data, and is working to develop streamlined submission processes for Genbank and SRA. For the time being, we suggest basing metadata and submission formatting on GISAID EpiCoV, which tends to be more comprehensive and structured. We will develop specific guidance for NCBI submissions. In the meantime, here are some general resources to help with NCBI data submission and metadata management.
Individual sequences can be submitted to NCBI using the following web form. Create an NCBI user account, and select "SARS-CoV-2 (through BankIt)".
NCBI has provided provisional guidance for SARS-CoV-2 sequence submissions to SRA and Genbank. Detailed instructions are available here. Any questions can be directed to NCBI staff here.
NCBI has indicated that they plan to develop a specific rapid submission process for SARS-CoV-2 sequences. In the meantime, I believe you should be able to follow the FDA/CFSAN submission protocol below, which includes links to appropriate interfaces and templates (with obvious changes for pathogen and project information).
The FDA Center for Food Safety and Applied Nutrition (CFSAN) has released a number of protocols as part of their GenomeTrakr Network that may be useful for NCBI sequence submission and metadata curation. While they are written specifically for laboratories that are conducting routine sequencing of foodborne bacterial pathogens, these protocols provide an overview of sequence submission to the NCBI pathogen portal, metadata and preflight data checks.
- NCBI submission protocol for microbial pathogen surveillance
- Populating the NCBI pathogen metadata template
- NCBI Data Curation - Pending release
Many users are already familiar with NIAID's wonderful METAGENOTE submission tool, which is frequently used to get microbial genomic and metagenomic datasets, and corresponding metadata organized and submitted to SRA. The NIAID Bioinformatics team has recently released a walkthrough on how to use the METAGENOTE platform for SARS-CoV-2 sequence read submissions. Detailed instructions here with an instructional video as well.
The GISAID EpiCoV Public Access repository is based on existing submission processes and data structures for large-scale influenza surveillance (GISAID EpiFlu). As such, submitters to EpiCoV will discover that several of the required metadata submission fields may be problematic. Nonetheless, a number of laboratories have been submitting sequences with the following:
| METADATA FIELDS (GISAID) | GUIDANCE |
|---|---|
Virus name |
USA/FL-UF-103/2020 (see above) |
Accession ID |
|
Type |
betacoronavirus |
Collection date |
YYYY-MM-DD |
Location |
USA / State / County? |
Additional location information |
|
Host |
Human |
Additional host information |
|
Gender |
(no guidance) |
Patient age |
(no guidance, could be binned) |
Patient status |
(no guidance) |
Specimen source |
(free text) |
Outbreak detail |
omit |
Last vaccinated |
omit |
Treatment |
omit |
At a minimum, we suggest that samples be submitted with collection date location host information attached. location, host, gender patient age are all required fields, and several of them likely constitute personally-identifiable information. While they cannot be left blank for submission, you can submit the record successfully (in both single or batch mode) by entering "unknown".
Note that for GISAID submissions, users must register for an account, and must successfully submit a single submission before being granted access to the bulk submission template and interface.
A copy of the current bulk submission template is available here.
To expand data included in national surveillance estimates, CDC would like to include SARS-CoV-2 sequences generated at U.S. public health laboratories that meet the baseline surveillance criteria. Baseline surveillance is achieved by sequencing specimens that represent geographic, demographic (e.g., age), and clinical (e.g., disease severity or outcome) diversity across a jurisdiction through a random selection of SARS-CoV-2-positive, diagnostic specimens. Sequences that meet the criteria for baseline surveillance analyses include those:
- Sampled randomly for genomic surveillance
- Not identified in a targeted sampling effort (details linked below)
- Sampled across targeted sequencing efforts to be representative of the community
For sequences to be correctly identified and ingested into the baseline surveillance analysis, they must be tagged appropriately during submission to public repositories. Detailed guidance and instructions are outlined in: Technical-Assistance-for-Categorizing-Baseline-Surveillance.pdf
For data linkage, we are proposing the following template, as a simple, lightweight line list of tab-separated values. If this consensus recommendation for data linkage is acceptable, a preformatted .TSV will be made available. We recognize that not all samples sent for sequencing have a PUID associated.
| SEQUENCE_NAME | GISAID_ID | GENBANK_ID | COLLECTION_DATE | PUID/COVID-ID |
|---|---|---|---|---|
| USA/CA-CDPH-999/2020 | EPI_ISL_999999 | MT99999999 | 2020-04-01 | 99999 |
In this simple proposed schema, GISAID ID or GENBANK ID and COLLECTION DATE are required fields, and our hope is to maximize PUID completion. All accession numbers, including PUID should be entered without any superfluous text or annotation.
- Open-source analytics tools for studying the COVID-19 coronavirus outbreak
- NU COVID-19 Resource Collection
- Global Initiative on Open-source Genomics for SARS-CoV-2
- Nextstrain hCoV-19
- UCSC SARS-CoV-2 browser
- CNCB 2019 Novel Coronavirus Resource (2019nCoVR)
- PANGO lineages
- Plylodynamics of SARS-CoV-2-GISAID subsamples
- US SPHERES Nextstrain builds
- Genomic dashboard information and examples
- SARS-CoV-2 PCR Primer List (Grubaugh Lab, Yale SPH)
- EDGE Bioinformatics: In-Silico Evaluation of Diagnostic Assays (LANL)
- Coronavirus Methods Development Group @ protocols.io
- Technical Outreach and Assistance for States Team (TOAST) 'menu' @ protocols.io
This repository constitutes a work of the United States Government and is not subject to domestic copyright protection under 17 USC § 105. This repository is in the public domain within the United States, and copyright and related rights in the work worldwide are waived through the CC0 1.0 Universal public domain dedication. All contributions to this repository will be released under the CC0 dedication. By submitting a pull request you are agreeing to comply with this waiver of copyright interest.
Unless otherwise specified, the repository utilizes code licensed under the terms of the Apache Software License and therefore is licensed under ASL v2 or later.
This source code in this repository is free: you can redistribute it and/or modify it under the terms of the Apache Software License version 2, or (at your option) any later version.
This source code in this repository is distributed in the hope that it will be useful, but WITHOUT ANY WARRANTY; without even the implied warranty of MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the Apache Software License for more details.
You should have received a copy of the Apache Software License along with this program. If not, see http://www.apache.org/licenses/LICENSE-2.0.html
Any source code forked from other open source projects will inherit its license.
This repository contains only non-sensitive, publicly available data and information. All material and community participation is covered by the Disclaimer and Code of Conduct. For more information about CDC's privacy policy, please visit http://www.cdc.gov/other/privacy.html.
Anyone is encouraged to contribute to the repository by forking and submitting a pull request. (If you are new to GitHub, you might start with a basic tutorial.) By contributing to this project, you grant a world-wide, royalty-free, perpetual, irrevocable, non-exclusive, transferable license to all users under the terms of the Apache Software License v2 or later.
All comments, messages, pull requests, and other submissions received through CDC including this GitHub page may be subject to applicable federal law, including but not limited to the Federal Records Act, and may be archived. Learn more at http://www.cdc.gov/other/privacy.html.
This repository is not a source of government records, but is a copy to increase collaboration and collaborative potential. All government records will be published through the CDC web site.
Updated: 20211020 @dmaccannell